Notification of permanent price reduction for Gemzar 200 mg and Gemzar 1 g

 

29 November 2019 – In 1876, Colonel Eli Lilly founded the pharmaceutical company that is devoted to innovative medicines. More than 140 years later, Lilly remains committed to providing quality medicines to the right patients at the right time.

In South Africa, we are proud of offering medicines that save patients’ lives and improve patient treatment outcomes.

Eli Lilly (SA) (PTY) Limited is pleased to announce a 36.6% permanent price reduction for Gemzar 200 mg and for Gemzar 1 g effective 29 November 2019. Gemzar has been in South Africa for 24 years for the management of NSCLC, breast cancer, pancreatic cancer, recurrent epithelial ovarian cancer, and transitional cell bladder cancer.[1]

Thank you for your continued commitment to making lives better for your patients. We hereby confirm our continued dedication in being your trusted partner in helping patients.

 

Should you have any further queries, please contact:

Yaksha Sewpersad

Oncology Brand Specialist

Eli Lilly and Company

+27 (11) 510 9300 | +27 (82) 302 5762

sewpersad_yaksha@lilly.com

Fharzana Khan

Market Access Manager: Oncology

Eli Lilly and Company

+27 (11) 510 9368 | +27 (83) 417 6280

khan_fharzana@lilly.com

 

Reference:

[1] Gemzar 200 mg and 1 g Package Insert.

Wildcard SSL